IDEXX LABORATORIES INC /DE Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax
IDEXX LABORATORIES INC /DE (IDXX) reported Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax of $3.01 million for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-10-31.
Discontinued › Notes › Derivative Instruments and Hedging Activities › Effect of Net Investment Hedge on Results of Operations
us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax · last filed 2019-10-31
- IDEXX LABORATORIES INC /DE gain (loss) on derivative used in net investment hedge, after tax for the quarter ending 2019-09-30 was $3.01M, a 441.80% increase year-over-year.
- IDEXX LABORATORIES INC /DE gain (loss) on derivative used in net investment hedge, after tax for the quarter ending 2019-06-30 was -$980.00K, a 121.88% decline year-over-year.
- IDEXX LABORATORIES INC /DE gain (loss) on derivative used in net investment hedge, after tax for the quarter ending 2019-03-31 was $1.48M.
- IDEXX LABORATORIES INC /DE gain (loss) on derivative used in net investment hedge, after tax for the quarter ending 2018-12-31 was $1.10M.
- IDEXX LABORATORIES INC /DE gain (loss) on derivative used in net investment hedge, after tax for fiscal 2018 was $3.92M.
- IDEXX LABORATORIES INC /DE gain (loss) on derivative used in net investment hedge, after tax for fiscal 2017 was -$8.35M, a 489.68% decline from fiscal 2016.
- IDEXX LABORATORIES INC /DE gain (loss) on derivative used in net investment hedge, after tax for fiscal 2016 was $2.14M, a 13.09% increase from fiscal 2015.
- IDEXX LABORATORIES INC /DE gain (loss) on derivative used in net investment hedge, after tax for fiscal 2015 was $1.89M.
| Period end | Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax 3 month | Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax 6 month | Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax 9 month | Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax 12 month |
|---|---|---|---|---|
| 2019-09-30 | $3.01M 10-Q · filed 2019-10-31 | $2.03M derived: sum of 2 quarters · filed 2019-10-31 | $3.51M 10-Q · filed 2019-10-31 | $4.61M derived: sum of 4 quarters · filed 2019-10-31 |
| 2019-06-30 | -$980.00K 10-Q · filed 2019-08-01 | $500.00K 10-Q · filed 2019-08-01 | $1.60M derived: sum of 3 quarters · filed 2019-08-01 | $2.15M derived: sum of 4 quarters · filed 2019-10-31 |
| 2019-03-31 | $1.48M 10-Q · filed 2019-05-01 | $2.58M derived: sum of 2 quarters · filed 2019-05-01 | $3.13M derived: sum of 3 quarters · filed 2019-10-31 | $7.61M derived: sum of 4 quarters · filed 2019-10-31 |
| 2018-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15 | $1.65M derived: sum of 2 quarters · filed 2019-10-31 | $6.13M derived: sum of 3 quarters · filed 2019-10-31 | $3.92M 10-K · filed 2019-02-15 |
| 2018-09-30 | $555.00K 10-Q · filed 2019-10-31 | $5.03M derived: sum of 2 quarters · filed 2019-10-31 | $2.82M 10-Q · filed 2019-10-31 | $1.37M derived: sum of 4 quarters · filed 2019-10-31 |
| 2018-06-30 | $4.48M 10-Q · filed 2019-08-01 | $2.26M 10-Q · filed 2019-08-01 | $811.00K derived: sum of 3 quarters · filed 2019-08-01 | -$1.22M derived: sum of 4 quarters · filed 2019-08-01 |
| 2018-03-31 | -$2.22M 10-Q · filed 2019-05-01 | -$3.67M derived: sum of 2 quarters · filed 2019-05-01 | -$5.70M derived: sum of 3 quarters · filed 2019-05-01 | -$9.47M derived: sum of 4 quarters · filed 2019-05-01 |
| 2017-12-31 | -$1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15 | -$3.49M derived: sum of 2 quarters · filed 2019-02-15 | -$7.25M derived: sum of 3 quarters · filed 2019-02-15 | -$8.35M 10-K · filed 2019-02-15 |
| 2017-09-30 | -$2.04M 10-Q · filed 2018-11-01 | -$5.80M derived: sum of 2 quarters · filed 2018-11-01 | -$6.89M 10-Q · filed 2018-11-01 | -$3.10M derived: sum of 4 quarters · filed 2019-02-15 |
| 2017-06-30 | -$3.77M 10-Q · filed 2018-08-01 | -$4.86M 10-Q · filed 2018-08-01 | -$1.07M derived: sum of 3 quarters · filed 2019-02-15 | -$1.80M derived: sum of 4 quarters · filed 2019-02-15 |
| 2017-03-31 | -$1.09M 10-Q · filed 2018-05-04 | $2.70M derived: sum of 2 quarters · filed 2019-02-15 | $1.97M derived: sum of 3 quarters · filed 2019-02-15 | $3.27M derived: sum of 4 quarters · filed 2019-02-15 |
| 2016-12-31 | $3.79M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15 | $3.06M derived: sum of 2 quarters · filed 2019-02-15 | $4.37M derived: sum of 3 quarters · filed 2019-02-15 | $2.14M 10-K · filed 2019-02-15 |
| 2016-09-30 | -$732.00K 10-Q · filed 2017-10-31 | $575.00K derived: sum of 2 quarters · filed 2017-10-31 | -$1.65M 10-Q · filed 2017-10-31 | $4.35M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | $1.31M 10-Q · filed 2017-08-01 | -$917.00K 10-Q · filed 2017-08-01 | $5.08M derived: sum of 3 quarters · filed 2018-02-16 | $4.69M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | $2.22M 10-Q · filed 2017-04-28 | $3.78M derived: sum of 2 quarters · filed 2018-02-16 | $3.38M derived: sum of 3 quarters · filed 2018-02-16 | $4.12M derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | $1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $1.16M derived: sum of 2 quarters · filed 2018-02-16 | $1.90M derived: sum of 3 quarters · filed 2018-02-16 | $1.89M 10-K · filed 2018-02-16 |
| 2015-09-30 | -$396.00K 10-Q · filed 2016-11-01 | $341.00K derived: sum of 2 quarters · filed 2016-11-01 | $340.00K 10-Q · filed 2016-11-01 | |
| 2015-06-30 | $737.00K 10-Q · filed 2016-08-02 | $737.00K 10-Q · filed 2016-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |